Држава: Канада
Језик: Енглески
Извор: Health Canada
ATORVASTATIN (ATORVASTATIN CALCIUM)
ALTAMED PHARMA
C10AA05
ATORVASTATIN
80MG
TABLET
ATORVASTATIN (ATORVASTATIN CALCIUM) 80MG
ORAL
4/30/100
Prescription
HMG-COA REDUCTASE INHIBITORS
Active ingredient group (AIG) number: 0133055004; AHFS:
CANCELLED PRE MARKET
2022-06-14
Page 1 of 53 PRODUCT MONOGRAPH PR ATORVASTATIN (ATORVASTATIN CALCIUM TABLETS) 10 MG, 20 MG, 40 MG AND 80 MG ATORVASTATIN LIPID METABOLISM REGULATOR Altamed Pharma Date of Preparation: 205-2900 Boul Cote-Vertu June 5, 2018 Saint-Laurent, Quebec H4R 3E8 Control# 215092 Page 2 of 53 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ............................................................................. 3 SUMMARY PRODUCT INFORMATION ............................................................................................. 3 INDICATIONS AND CLINICAL USE ................................................................................................... 3 CONTRAINDICATIONS ........................................................................................................................ 5 WARNINGS AND PRECAUTIONS ....................................................................................................... 5 ADVERSE REACTIONS ....................................................................................................................... 11 DRUG INTERACTIONS ....................................................................................................................... 14 DOSAGE AND ADMINISTRATION ................................................................................................... 21 OVERDOSAGE ..................................................................................................................................... 22 ACTION AND CLINICAL PHARMACOLOGY .................................................................................. 22 STORAGE AND STABILITY ............................................................................................................... 25 SPECIAL HANDLING INSTRUCTIONS ............................................................................................ 26 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................................. 26 PART II: SCIENTIFIC INFORMATION ................... Прочитајте комплетан документ